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PRELIMINARY AND SHORT REPORT SECTION
EFFECT OF STILBAMIDINE THERAPY ON EXPERIMENTAL BLASTOMYCES
DERMATITIDIS INFECTIONS IN MICE*
MA11GARET KING WEST, A.B. AND W. F. VERWEY, SC.D.
Recent reports in the literature have indicated that the use of stilbamidine (4,4'-di-
amidinostilbene diisethionate) in clinical cases of blastomycosis has been measurably
effective (1, 2, 3). Heilman, using an experimental blastomyces infection in mice, showed
that stilbamidine exerted a suppressive effect on the pulmonary infection caused by intra-
venous injection of Blastomyces dermatitidis (4). A report by Schwarz and Adriano (5)
indicates that experimental therapy with stilbamidine against blastomyces infections
in mice was ineffective. It is believed that experiments carried out in this laboratory on the
effect of stilbamidine against experimental infections of B. dermatitidis in mice may serve
to correlate these two varying points of view.
METNODS AND MATERIAL
A series of experiments was run with four-fold dosage increments of stilbamidine as
therapy for blastomyces-infected mice and in uninfected mice for toxicity control in order
to titrate the amount of compound needed to protect 50% of the infected mice (PD 50),
and to determine the amount that would be toxic for 50% of the uninfected mice (TD50).
All solutions of stilbamidine used for treatment were aqueous, made fresh daily in order to
eliminate the possibility of deterioration of the material. Ten Carworth Farms (CFI)
female albino mice, 14—16 gins., were used on each dosage level and for controls. The mice to
be infected were given an intraperitoneal injection of 0.5 ml. of a 10 suspension in 5%
mucin of B. dermatitidis taken from a five day blood agar yeast phase culture which had been
washed with saline. The cells were resuspended in saline and adjusted to a Klett-Summerson
Colorimeter reading of 300 with a green filter. Treatment was begun immediately at the time
of infection with 0.1 ml. intraperitoneal doses of stilbamidine and continued once daily
thereafter for a total of eleven doses. All mice were observed for at least forty-two days
and survivors were then sacrificed and observed for gross pathology.
RESULTS
The intraperitoneal toxicity of stilbamidine gave a TD50 of .839 mg. per dose by the
Reed & Muench method (6). Levels of 5.0 mg. per dose, 1.25 mg., 0.312 mg., and 0.078 mg.
were given daily for eleven days. The 5.0 mg. mice died within an hour after the first injec-
tion and seven of the mice that received 1.25 mg. died within one day. All other mice sur-
vived through the forty-second day, when they were discarded. Table I shows the
distribution of deaths from toxicity and the mean survival times for each level
of the compound.
A protection experiment, run in four-fold dilutions at lower levels, resulted in a PD50
of 0.06 mg. according to the method of Reed and Muench (6). The dosage levels began at
0.5 mg. per dose to 0.007mg., one dose daily for eleven days. At the end of the forty-two day
observation period, the PD50 was calculated and the surviving infected animals
were autopsied.
It will be seen by the mean survival times listed in Table II that even at the lower doses
where the treatment was not sufficient to protect the mice, the increase in the mean survival
times was quite marked. Toxicity control mice receiving 0.5 mg/dose on this same experi-
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TABLE I
,Stilbamidine toxicity
MG/DOSE SURVIVALS/TOTAL 61ST
0.078
0.312
1.25
5.0
10/10
10/10
3/10
0/10
>42
>42
16.4
<1.0
TD60 = .839 mg.
TABLE II
Stilbamidine therapy
TRZATED SIT 61ST AUTOPSY OP SURVIVINGMICE A1'TER 42 DAYS
0.007 mg.
0.031
0A25
0.5
Control
3/10
1/10
7/10
0/10
0/10
31.7
32.2
39.6
9.8
17.0
3 Normal
1±
5 Normal; 2±
PD60 0.06 mg.
ment showed 100% survival at this level; however, these figures may be reconciled, as ex-
plained in the Discussion. Autopsies performed on the micesurviving the infection through
treatment were graded according to the gross pathology. Animals that had no gross evidence
of caseation were rated as being normal. Single small caseated nodules were rated as being
In no animal was there found any evidence of extensive infection.
In another experiment in which frequency of dosage was compared, stilbamidine given
intraperitoneally for nine days twice a day showed no difference in protection
from stilbamidine given intraperitoneally once a day for eleven doses.
DISCUSSION
Stilbamidine therapy has been successful in this laboratory against experimental B.
dermatitidis infections in mice. Protection has been found in a preliminary experiment
when the dose was as low as 0.0625 mg. per day if the treatment was started at the time the
infection was given. It has been observed that in an intraperitoneal infection of the type
used in this laboratory, the first gross signs of pathology, caseated nodules in various por-
tions of the peritoneal cavity, may be seen as early as the fourth day after infection, so that
the disease must be firmly established and disseminated throughout the body even earlier.
The mean survival times of the controls in our experiments have been usually from 15—17
days with deaths from 8—25 days following intraperitoneal infections, while death from an
intravenous infection occurs several days earlier. Under these conditions, subcutaneous
treatment begun the eighth day after intravenous infection, as done by Schwartz (5), would
be unlikely to show the therapeutic value of the drug, as the infection would be well en-
trenched and almost at its terminal point before treatment was begun. Even when treat-
ment is instituted at the same time that the animals are infected, late deaths may be
expected to occur, since it is seldom that 100% of the animals treated are sterilized. The
prolongation of life with stilbamidine therapy is indisputable in the treated animals, as
evidenced by the mean survival times, and a majority of the animals may be considered
cured, if the lack of pathology upon autopsy may be used as an index. Since a toxicity level
is run simultaneously with the treatment level, there is no danger of confusing deaths from
infection with toxicity deaths. At the border-line toxicity levels deaths may be obtained in
the infected treated mice where the uninfected treated (toxicity) mice survive. Presumably
border-line toxicity is further enhanced by the added stress of infection.
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It is dangerous to attempt to translate the activity of any therapeutic agent in the labo-
ratory animal into terms of efficacy in the human patient, as the response of these two
hosts may vary widely, but the experimental response may be used to indicate the clinical
approach. Under the test conditions in this laboratory stilbamidine is of considerable value
in the treatment of experimental B. dermatitidi8 infections in mice, and in spite of the re-
ported toxicity in humans, would appear to be worthy of further study in the clinical case
of blastomycosis. Several authors, including Heilman (4) and Snapper (7), have expressed
an opinion that 2-hydroxystilbamidine will have the therapeutic value of stilbamidine with
somewhat lessened toxicity. Comparative studies of these two drugs are in progress in
this laboratory and will be reported at a later date.
SUMMARY
A report is given of experimental therapy with stilbamidine against a B. dermatitidis
infection in mice. Female albino mice were infected intraperitoneally with a yeast phase
suspension of B. dermatitidis in mucin and treated intraperitoneally with stilbamidine daily
for eleven days. The TD50 was 0.839 mg. per dose and the PD50 was 0.06 mg. per
dose. Further study of stilbamidine as a possible agent for the treatment of blastomycosis
in humans appears to be justified.
We would like to express our appreciation to the William S. Merrel Company for sup-
plying the stilbamidine and 2-hydroxystilbamidine used in these experiments.
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